Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEX-18
- Development stage
- Phase 1
- Lead developer
- Nanexa
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Subcutaneous
01
Overview
NEX-18 is a long-acting, injectable depot formulation of azacitidine developed using Nanexa's proprietary PharmaShell drug delivery technology. The aim of NEX-18 is to simplify the treatment regimen for patients with myelodysplastic syndrome (MDS), a hematological cancer primarily affecting the elderly, by reducing the current standard of seven daily subcutaneous injections per month to a single monthly injection. The PharmaShell coating enables controlled and sustained release of azacitidine over several weeks, potentially reducing acute side effects associated with high initial drug concentrations and improving patient convenience and adherence. Clinical development was paused due to moderate skin reactions at the injection site; subsequent preclinical studies identified potential solutions, and reformulation efforts are ongoing[1][2][3][4][6].
- Other names
- azacitidineNEX-18aNEX18aNEX 18aNEX-18NEX18NEX 18
02
Targets
DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on NEX-18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEX-18.